BNTC vs. JANX, EVO, STOK, LENZ, SNDX, SION, XERS, TSHA, ZYME, and NUVB
Should you be buying Benitec Biopharma stock or one of its competitors? The main competitors of Benitec Biopharma include Janux Therapeutics (JANX), Evotec (EVO), Stoke Therapeutics (STOK), LENZ Therapeutics (LENZ), Syndax Pharmaceuticals (SNDX), Sionna Therapeutics (SION), Xeris Biopharma (XERS), Taysha Gene Therapies (TSHA), Zymeworks (ZYME), and Nuvation Bio (NUVB). These companies are all part of the "pharmaceutical products" industry.
Benitec Biopharma vs. Its Competitors
Benitec Biopharma (NASDAQ:BNTC) and Janux Therapeutics (NASDAQ:JANX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.
52.2% of Benitec Biopharma shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 1.3% of Benitec Biopharma shares are held by company insiders. Comparatively, 8.1% of Janux Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, Janux Therapeutics had 3 more articles in the media than Benitec Biopharma. MarketBeat recorded 5 mentions for Janux Therapeutics and 2 mentions for Benitec Biopharma. Janux Therapeutics' average media sentiment score of 0.67 beat Benitec Biopharma's score of 0.34 indicating that Janux Therapeutics is being referred to more favorably in the news media.
Benitec Biopharma has higher earnings, but lower revenue than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks.
Benitec Biopharma presently has a consensus price target of $24.80, indicating a potential upside of 55.97%. Janux Therapeutics has a consensus price target of $78.31, indicating a potential upside of 176.90%. Given Janux Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Janux Therapeutics is more favorable than Benitec Biopharma.
Benitec Biopharma has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 2.82, suggesting that its share price is 182% more volatile than the S&P 500.
Janux Therapeutics' return on equity of -11.48% beat Benitec Biopharma's return on equity.
Summary
Janux Therapeutics beats Benitec Biopharma on 12 of the 15 factors compared between the two stocks.
Get Benitec Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BNTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Benitec Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:BNTC) was last updated on 10/16/2025 by MarketBeat.com Staff
